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ORIGINAL ARTICLE

Mechanisms, models and biomarkers in amyotrophic lateral sclerosis
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Abstract
The last 30 years have seen a major advance in the understanding of the clinical and pathological heterogeneity of amyotrophic lateral sclerosis (ALS), and its overlap with frontotemporal dementia. Multiple, seemingly disparate biochemical
pathways converge on a common clinical syndrome characterized by progressive loss of upper and lower motor neurons.
Pathogenic themes in ALS include excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, altered
energy metabolism, and most recently RNA mis-processing. The transgenic rodent, overexpressing mutant superoxide
dismutase-1, is now only one of several models of ALS pathogenesis. The nematode, fruit fly and zebrafish all offer fresh
insight, and the development of induced pluripotent stem cell-derived motor neurons holds promise for the screening of
candidate therapeutics. The lack of useful biomarkers in ALS contributes to diagnostic delay, and the inability to stratify
patients by prognosis may be an important factor in the failure of therapeutic trials. Biomarkers sensitive to disease activity might lessen reliance on clinical measures and survival as trial endpoints and reduce study length. Emerging proteomic
markers of neuronal loss and glial activity in cerebrospinal fluid, a cortical signature derived from advanced structural and
functional MRI, and the development of more sensitive measurements of lower motor neuron physiology are leading a
new phase of biomarker-driven therapeutic discovery.
Key words: ALS, biomarkers, pathogenesis, neuroimaging, neurophysiology

Introduction
There is an intense need to establish biomarkers
sensitive to diagnosis, prognostic stratification and
disease activity of ALS (Table I). The diagnosis of
amyotrophic lateral sclerosis (ALS) currently
depends upon the opinion of an experienced
neurologist, and the exclusion of potential mimic
disorders. In the context of progressive weakness,
where there are typical upper (UMN) and lower
motor neuron (LMN) signs within the same body

region, there is little diagnostic doubt and few tangible mimics. However, such obviously mixed
clinical signs may not be apparent at presentation
(or indeed ever) for a large proportion of patients,
who are nonetheless considered to form part of
the wider syndrome of ALS (1). This syndrome is
currently unified by the post mortem finding of
cytoplasmic inclusions of the protein TDP-43,
with the notable exception of those with mutant
SOD1 gene-associated ALS (approximately 1% of
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Table I. Types of biomarker in ALS, their value and the current gold standards.
Biomarker type
Diagnostic
Prognostic

Monitoring

Value

Current benchmarks

Initiate therapy earlier;
Exclude ALS
Identify patterns of progression:
1. Improved stratification in therapeutic trials
2. Timely intervention and optimal care
e.g. gastrostomy, non-invasive ventilation,
cognitive support
Identify ineffective drugs earlier

Neurological history & examination
Electromyography (Revised El Escorial/Awaji criteria)131
Diagnostic latency
Neurological evaluation (e.g. clinical phenotypes)
Cox modelling of clinical variables132,133

all cases) in whom the disease is nonetheless clinically indistinguishable (2). The failure of multiple
drugs tried for the treatment of ALS may in part
be a function of their application relatively late
in the course of the disease, given the average
diagnostic delay of one year (3). It is not yet
known when the initial pathological changes of
ALS begin, but it seems likely that the clinical
manifestations occur significantly downstream of
what may be rapidly irreversible primary events
at the cellular level. Earlier diagnosis would
permit introduction of therapies nearer to these
initiating events.
ALS is usually an apparently sporadic disorder
and the insidious clinical onset involves symptoms
common to more benign disorders, which means
that a significant proportion of the diagnostic
latency may remain inaccessible. At the time of
diagnosis, however, there is additional value in
identifying biomarkers sensitive to the recognized
variation in progression rate. Although the median
survival from symptom onset in ALS is less than
three years, the second half of the survival curve is
longer, and beyond a decade for at least 5% of
patients. The presence of relatively ‘pure’ UMN or
LMN clinical signs is associated with longer survival (4,5), with the rare UMN-only variant primary lateral sclerosis consistently at the extreme
end of long survival. However, such clinical findings cannot be reliably used prognostically in isolation. A quantifiable prognostic measure might also
be used to stratify patients within clinical trials to
detect meaningful benefit in the shortest time.
Knowledge of an individual patient’s course at the
time of diagnosis would facilitate effective care
planning and resource targeting.
Finally, biomarkers sensitive to disease activity
are the most needed. At present, clinical trials in ALS
generally rely on tracheostomy-free survival, functional status such as the revised ALS Functional Rating Scale (ALSFRS-R), or both, as the primary
outcome measures. Such trials are lengthy (12–18
months typically) and may be prohibitively costly. A
number of methods have been proposed to optimize
and shorten such studies (6), but a robust, quantitative monitoring biomarker would have obvious value
in this regard.

Revised ALS Functional Rating Score134
(Electrical impedance myography emergent102)

Biological themes
With the linking of familial ALS to several apparently disparate genes, it seems increasingly likely that
ALS represents a common final endpoint. A deeper
understanding of the common molecular pathways
involved in ALS pathogenesis would facilitate the
identification of biomarkers. Three genes linked to
familial ALS in recent years, namely TARDBP, FUS
and C9orf72, indicate a potentially pivotal role for
RNA mis-processing in the pathogenesis of ALS (see
Al-Chalabi et al., companion paper). Downstream of
these events, cellular biological studies over the last
two decades have led to the development of multiple
interconnected pathogenic themes in ALS (7).

Excitotoxicity
Excitotoxicity encapsulates a process of neuronal
death ultimately mediated by cellular calcium influx,
triggered via excessive stimulation of receptors for
glutamate. The finding of raised levels of glutamate
in the CSF in ALS (8), with a sensitivity of only 40%
in a later study and correlation with disease severity
(9), provides support for this.
The astrocytic glutamate transporter EAAT2 is
responsible for the clearance of synaptic glutamate,
and its knockout in transgenic mice results in neuronal death (10). Reduced levels of spinal cord
EAAT2 protein have been noted in end-stage rodent
transgenic models of ALS (11,12), with abnormalities of EAAT2 protein expression demonstrable in
up to 80% of human post mortem brain and spinal
cord tissue (13). EAAT2 receptor dysfunction has
been directly linked to mutant (but not wild-type)
SOD1 in the presence of hydrogen peroxide (14).
Overexpression of EAAT2 in mutant SOD1 transgenic mice then delayed the onset of motor deficits
(15,16). This role for astrocytes supports the view
that motor neuron degeneration in ALS is not cellautonomous. Although the exact mechanism of
action is uncertain, the only disease-modifying drug
in ALS to date, namely riluzole, appears to have
broadly anti-glutamatergic activity (17).
Glutamate acts through inotropic (NMDA,
AMPA and kainate) and metabotropic receptors
(MGluRs), and the relative contribution of these to
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ALS pathogenesis remains uncertain. The development of novel selective positron emission tomography (PET) ligands may provide clarification. It is
possible that excitotoxicity arises in ALS as a result
of wider ‘upstream’ impairments of energy metabolism in ALS so that ‘normal’ levels of glutamate
become toxic. There is also a body of evidence,
including from in vivo neuroimaging, indicating an
overall loss of neuronal inhibitory influence in ALS,
perhaps through a primary interneuronal dysfunction, resulting in excitotoxicity through less balanced
glutamatergic activity (18).
Oxidative stress
Oxidative stress arises from an alteration in the balance between the generation of reactive oxygen species (ROS) and their removal, together with the
ability of the biological system to remove or repair
ROS induced damage. The cumulative effect of oxidative stress in aged non-replicating neurons, may be
one important factor that tips the balance of homeostatic control mechanisms from an ability to cope
with a toxic insult such as the presence of a diseasecausing mutation, into a vicious cycle of cellular
injury culminating in neuronal death and the onset
of neurodegeneration in middle or later life. Oxidative stress causes structural damage (including DNA
(19)) and also changes in redox-sensitive signalling
pathways. The initial interest in the role of oxidative
stress in ALS (20) was given new impetus with the
discovery that mutations in SOD1, which encodes a
major anti-oxidant defence protein, accounted for
approximately 20% of cases of familial ALS (21). It
is clear that oxidative stress interacts with and potentially exacerbates other pathophysiological processes
contributing to motor neuron injury, including excitotoxicity, mitochondrial impairment, protein aggregation, endoplasmic reticulum stress and alterations
in signalling from astrocytes and microglia. Several
potential markers of free radical damage have been
found in the CSF and blood from ALS patients
(reviewed in (22)), and also in urine (23).
Cellular ROS are generated as by-products of
aerobic metabolism, predominantly due to leakage
of electrons from the mitochondrial respiratory
chain, but with contributions from other intracellular enzyme systems including xanthine oxidase
and cytochrome P450. ROS that are initially formed
such as superoxide and hydrogen peroxide may
undergo further reaction to produce more potent
oxidant species including peroxynitrite and hydroxyl
radicals. Biochemical indices of oxidative damage
to proteins, lipids and DNA in excessive quantities
compared to controls, can be found in post mortem
tissue from apparently sporadic and SOD1-related
familial cases. Oxidative damage to RNA species
has also been documented, adding to the evidence
that alteration in mRNA processing is an important pathophysiological mechanism in ALS (24).
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Indices of oxidative damage are also present in cellular and murine models of SOD1-related ALS, and
interestingly the SOD1 protein itself appears to be
particularly susceptible to oxidative post-translational modification. The recent development of cellular models of mutant TDP-43-related ALS
indicates that the presence of mutant TDP-43 also
provokes oxidative stress within motor neuronal
cell lines (25).
Sources of oxidative stress in ALS have been
investigated most thoroughly in mutant SOD1
(mSOD1) models, where several aberrant oxidative
reactions have been proposed. However, enzymatically inactive SOD1, depleted of copper loading, is
still capable of causing motor neuron degeneration,
and mSOD1 may cause oxidative stress by mechanisms beyond its own catalytic activity (26). mSOD1
within microglia increases superoxide production by
NADPH oxidase (Nox) enzymes. SOD1 stabilizes
Rac1-GTP in the activated Nox2 complex, and
mutant SOD1 locks Rac1 into its active state, with
resultant prolongation of ROS production (27).
Nox2 expression is increased in mSOD1 mice and
human ALS, and survival of SOD1-G93A mice is
extended by knock-out of either Nox1 or Nox2. The
transcription factor Nrf2 (nuclear erythroid-2related factor2) is a master regulator of the antioxidant response and responds to oxidative stress by
binding and up-regulating anti-oxidant response
element genes. Recent evidence has emerged that
Nrf2-ARE signalling may be dysregulated in models
of SOD1-related ALS and in the CNS of ALS
patients (28).
A meta-analysis of therapeutic interventions in
the mSOD1 mice up to 2007 concluded that antioxidant therapies were the class of drug most effective at improving survival (29). In human ALS,
anti-oxidants have not yet shown benefit, although
the reported trials have often been of suboptimal
design, and new in vitro screening methods may be
able to generate future candidates (30).
Mitochondrial dysfunction
Mitochondria are critical for cell survival, acting as
an energy source of the cell, buffering intracellular
calcium, and regulating apoptosis. Damage to mitochondria selectively within tissues affected in ALS
has been widely observed, especially in inherited disease caused by mutations in SOD1. Mitochondrial
abnormalities may be a trigger or a consequence of
the neurodegenerative process and the precise mechanisms remain uncertain (31,32). Mutant SOD1 is
localized in mitochondria, and accumulates on the
outer membrane and inside the intermembrane
space (33). Mutant SOD1 and other mutant proteins, such as TDP-43, may cause mitochondrial
dysfunction by affecting the expression of mitochondrial proteins involved in energy metabolism. Mitochondria can also be affected by external SOD1
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interfering with signalling and transport of the organelles. Key surface components inhibited by misfolded
mSOD1 include the following:
• the voltage-dependent anion channel (VDAC1),
the conductance of which is inhibited (34);
• the translocase of the outer membrane (TOM)
transport complex, which is responsible for the
import into mitochondria of over 1000 proteins made in the cytoplasm (35);
• Bcl2, an anti-apoptotic protein normally associated with mitochondria (36).
As a consequence of mSOD1 damage, mitochondria are non-uniformly distributed along axons of
motor neurons (37).
The selective association of mSOD1 with mitochondria in cells of affected tissues remains uncertain, as is whether differences in mitochondria or
cytoplasmic components (e.g. chaperones) may be
responsible for tissue-specific abnormalities of protein folding. Drugs targeting mitochondrial properties (e.g. calcium conductance, biogenesis, fission,
fusion, or transport) might provide therapeutic benefit. Mitochondrial modulators are a new class of
potential therapeutic. Olesoxime promotes survival of
mutant motor neurons in vitro (38), possibly by binding to the mitochondria, targeting VDAC and the
benzodiazepine receptor. However, a recent human
phase III study of olesoxime in ALS proved negative.
Dexpramipexole is a mitochondrial ‘membrane stabilizer’ (39,40), but a human phase III study in ALS
also proved negative.
Neuroinflammation
Inflammatory mechanisms and immune reactivity
are hypothesized to play a role in the pathogenesis
of ALS (41). In experimental models, the progression of ALS has been linked to microglial cell/
macrophage activation in the spinal cord. Studies in
patients with ALS have found elevated markers of
inflammation (CRP, interleukin-6 and 13, macrophage chemotactic protein-1 (MCP-1)) (42). Levels of MCP-1 and other chemokines have also been
detected in the CSF of ALS patients (43,44). Such
proteins may contribute to the amplification or
possibly initiation of inflammation during ALS.
Additionally, systemic macrophage activation and
alteration of macrophage surface markers have
been linked to disease progression (45). Donor macrophages were present at sites of neuron loss after
bone marrow transplantation, suggesting an ongoing
migration of blood monocytes in patients with ALS
(46). Macrophage activation markers in ALS blood
are similar to those identified in the blood of patients
with AIDS dementia where macrophages invading
the CNS have been proven to induce neurodegeneration. Studies with Neuraltus Pharmaceuticals
NP001, a small molecule regulator of macrophage
activation in the SOD1 mouse model, demonstrated

longer survival compared with controls (19 days,
p ⫽ 0.01) and slowing of the decline in neurological
score. Phase II studies in humans are currently
underway.
Altered energy metabolism
Studies in animal models have convincingly demonstrated that whole body energy physiology is
impaired in ALS, and that this contributes to
motor neuron degeneration (47,48). In patients,
much of the evidence that similar events occur is
correlative. Most importantly, body mass index
and overall nutritional status at disease onset
appear to be strong predictors of survival of patients
(49,50). Circulating blood lipids are positively correlated with survival (51,52) or functional status
(53). Whether these statistical associations might
translate into a sensitive and specific biomarker
awaits further investigation. Multiple confounders
might blur the sensitivity and specificity of such
markers. First, dysphagia as a consequence of bulbar involvement, has a strong impact on nutritional
status, and is on its own a sign of poorer prognosis.
Secondly, impaired glucose tolerance has been
observed in ALS patients, and it is unknown
whether abnormalities in glucose metabolism
influence survival in ALS. Finally, regional and
national dietary specificities are very likely to have
strong influence on blood lipids and nutrition, and
may confound the observed effects. Metabolomic
studies in the blood of ALS patients and animal
models might delineate a core set of metabolites
that could be useful as biomarkers. A recent
metabolomics study identified altered metabolites
indicative of disrupted mitochondrial function and
increased carbohydrate and lipid metabolism in
ALS patients (54). Alternatively, imaging methods,
in particular MRI of adipose tissues (55), DEXAscan or CT may help to determine whether energy
stores provide a biomarker related to energy
metabolism.
Disease models
For human neurodegenerative diseases it is not currently possible to study cellular pathological processes in real time, or safely and repeatedly remove
tissue for analysis. The ability to study cellular
molecular processes, identify key pathways for intervention, and assess multiple candidate therapies over
short periods of time, depends on the development
of disease models. The ability to express both wildtype and mutant human genes in non-human cells
and transgenic animals has provided a variety of possibilities for modelling many neurodegenerative disorders, including ALS (56,57). The discovery of
linkage to the SOD1 gene of some cases of familial
ALS led rapidly to the creation of an overexpressing
mutant SOD1 transgenic mouse (58). This and other

Saccharomyces cerevisiae
SOD1, TARDBP, or
FUS-related transgenics;
Also used as a screening
model for novel
RNA-binding-related genes

Caenorhabditis elegans SOD1,
TARDBP, or
FUS-related transgenics

Drosophlia melanogaster SOD1,
TARDBP, or
FUS-related transgenics

Danio rerio SOD1, TARDBP, or
FUS-related transgenics

Mus musculus ⬎⬎ Rattus
norvegicus SOD1 or
TARDBP-related transgenics

Worm

Fruit fly

Zebrafi sh

Rodent

Specifics

Yeast

Model

ALS-like pathology

Mutant SOD1 linked to MN
loss and dysmorphic NMJs;
Mutant TDP-43 linked to
decreased motor axon
length and branching;
Mutant FUS linked to
cytoplasmic inclusions
Mutant SOD1 linked to gliosis,
ubiquitinated SOD1 inclusions,
mitochondrial vacuolation,
axonal and MN loss;
WT and mutant TDP-43 more
variably linked to cellular
aggregates or MN loss

Variable effects of both
wild-type and mutant
TDP-43 & FUS on aggregate
formation, dendritic branching,
and NMJ dysfunction
depending on tissue expression

Mutant SOD1 disrupts
mitochondrial
homoeostasis;
Recapitulation of
TDP-43 & FUS
aggregation with
identification of modulators
Increased sensitivity to
oxidative stress in
presence of mutant SOD1,
with aggregate formation;
Aggregates of mutant
TDP-43 & FUS

Table II. Models of ALS pathology, and their key features.

Progressive locomotor
abnormalities with
hind-limb weakness
and muscle wasting
from ˜ 3 months
WT and mutant TDP-43
less consistently linked
to any motor
abnormalities and
muscle atrophy

Progressive
‘incoordination’ &
paralysis over
hours-days in
overexpressing mutant
(especially
phosphorylated)⬎ wildtype TDP-43 & FUS
(and only mutant
SOD1) worms
Variable effects of both
wild-type and mutant
SOD1, TDP-43 &
FUS on larval
locomotor function
depending on tissue
expression
Mutant SOD1 associated
with motor
abnormalities and
muscle atrophy

NA

Potentially relevant
physical features

Consistent motor
phenotype; readily
available, low
maintenance;
homologous basic
neuromuscular
structures to humans;
short life cycle

Readily available, low
maintenance;
homologous basic
neuromuscular
structures to humans;
short life cycle

Readily available, low
maintenance;
homologous basic
neuromuscular
structures to humans;
short life cycle

Readily available, low
maintenance;
homologous basic
cellular structures to
humans; non-animal;
rapid turnover; high
throughput
Readily available, low
maintenance;
homologous basic
neuromuscular
structures to humans

Advantages

Costly infrastructure;
some ethical concerns
Poor translation of
therapeutic response in
SOD1 mouse to human
studies so far
TDP-43 models show
limited motor
phenotype

Variable effects and
limited human clinical
similarity

Variable effects and
limited human clinical
similarity

Variable effects and
limited human clinical
similarity

Cellular toxicity arising
simply from overexpression of human
proteins; facultative
aerobe unlike human
cells

Disadvantages

(Continued)

Reviewed in56,146

Reviewed in56
See also144,145

Reviewed in56
See also140 –143

Reviewed in56
See also138,139

135 –137

Key references
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148

147

Macaca fascicularis over-expressing
human TDP-43 via adenovirus
to cervical cord
Monkey

Cytoplasmic mislocalization of
TDP-43; cystatin-C positive
aggregates

Progressive motor
weakness of distal
upper limbs with
fasciculation and
wasting

Closest species to
humans physically and
behaviourally

Ethical concerns,
availablity and
infrastructure issues;
long latency to
symptoms; limited
relevance to nonSOD1-related ALS
Major ethical concerns
and infrastructure
issues; limited
relevance to ‘slowlydeveloping’ human
ALS
Similar to human
SOD1-related ALS in
being a delayed
adult-onset disorder
Adult-onset progressive
spastic myelopathy
affecting pelvic girdle,
leading to eventual
flaccid quadriparesis
‘Canine degenerative myelopathy ’:
Pembroke Welsh corgi, Boxer,
Rhodesian ridgeback, German
Shepherd, & Chesapeake Bay
retriever all homozygous for
SOD1 ‘E40K’ missense mutation
Dog

Lateral cord white matter
myelin and axonal loss;
Neuronal cytoplasmic inclusions
binding anti-SOD1 antibodies

Specifics
Model

ALS-like pathology

Potentially relevant
physical features

Advantages

Disadvantages

Key references
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Table II. (Continued )
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models are summarized in Table II. Such models do
not, as yet, capture pathogenesis at a systems level,
and no one model has yet been able to reproduce all
of the pathological and behavioural features of ALS.
Nonetheless, they have provided a valuable platform
for testing many of the pathogenic hypotheses outlined earlier in this article, with hope for the future
development of assays for high-throughput screening
of therapeutic candidates.
Induced pluripotent stem cells
The generation of motor neurons from induced
pluripotent stem cells (iPSCs), in turn derived
from the skin fibroblasts of ALS patients (59), has
marked a major advance in modelling pathogenesis
in ALS, with potential for high-throughput therapeutic assessments. Encapsulated by the phrase
‘disease in a dish’, iPSCs carrying the TDP-43
‘M337V’ mutation have already been shown to
reproduce several key aspects of TDP-43-related
proteinopathies, including aggregate formation and
reduced cell survival (60). The ability to generate
not only motor neurons but also other nonneuronal cell types (including astrocytes, oligodendrocytes, microglia), will allow for versatility in
teasing out cell-specific contributions to disease
development. iPSCs from patients with familial
ALS have already been made available to researchers at the NINDS Repository, thus allowing for
the study of ALS arising from numerous SOD1,
FUS, and FIG4 mutations.
However, a number of challenges remain with
regard to human iPSC uses for investigation into
ALS biology. Currently, the long periods of time
required to generate human neural cells (for example, astrocytes) results in significant expense and
often complex experimental paradigms. Because
iPSCs are derived from individual patients, careful
assessment of the sample sizes studied should be
considered before broad conclusions can be made
about disease from a single iPSC source. The impact
of the patients’ age on the resulting iPSC remains
unclear. If used to screen for potentially relevant
ALS drug targets, standardization of cell lines across
laboratories will be important for validation of drug
effects. Future aims include the development of
more complex integrated structures, for example the
neuromuscular junction using muscle and neuronal
cell cocultures (61).
Despite these challenges, it is likely that more
efficient derivation of iPSC will be developed, thus
shortening the time and expense currently associated with creating iPSC lines. As sources of iPSC
become more readily available to the research community, investigators with a wide range of research
interests will be able to draw on a range of ALS
genotypes and phenotypes thus allowing for the
identification of new ALS relevant disease targets for
therapeutics.

Mechanisms, models and biomarkers in ALS
Tissue and fluid biomarker sources
Biofluids
The range of human biofluids useful in proteomic
studies to identify an ALS biomarker ‘signature’,
includes CSF, blood, urine, and saliva (62). CSF is
an excellent biofluid for biomarker discovery due to
its approximation to the cells and brain and spinal
cord regions exhibiting cell death during ALS. Blood,
while more accessible, has greater protein complexity with greatly reduced concentrations, compared to
CSF, of those proteins fundamentally involved in
neuronal function.
During the past decade there has been a large
increase in the number of ALS biomarker studies
using CSF as well as blood (22). Most of these studies have examined changes of individual proteins in
the CSF of ALS versus healthy control or other neurologic disease subjects, typically using a gel-based
system or ELISA (63). However, most are limited by
the number of samples used in the analysis, choice
of control subjects, and typically the lack of verification in a separate cohort of patients. A number of
more recent studies have used mass spectrometry or
cytokine profiling to identify panels of candidate
protein biomarkers in the CSF (43,64). Metabolomic approaches have been used to explore metabolic
differences between ALS and control subjects in
CSF and serum (54,65 – 67). Early changes in patient
metabolism and protein levels or posttranslational modifications offer a means to both
identify ALS at an early stage and to develop biomarkers to follow during disease progression.
At present, CSF candidate biomarkers in ALS
can be grouped into those that reflect neuronal loss
and those indicative of neuroinflammatory (glial)
processes. For the former, neurofilaments have been
the most reproducible (68 – 70). CSF TDP-43
appears to fall with disease progression in typical
ALS (71), with lower values found in cases of ALSFTD (72). The significance of finding reduced CSF
transthyretin and cystatin C in ALS is uncertain
(64). The latter is the essential constituent of the
‘pathognomonic’ Bunina body inclusion seen histopathologically in ALS and has been detected at
increased levels in ALS plasma (73).
While several molecules linked to neuroinflammatory pathways have been reported as increased in
ALS patient CSF, each has limited sensitivity in isolation and many studies have not been reproduced.
A panel of cytokines, specifically interleukins 2, 6,
10, 15 and granulocyte-monocyte colony stimulating
factor (GM-CSF) was nearly 90% accurate in distinguishing ALS patients from healthy controls (43).
Other studies have also supported the concept of
combining markers to improve accuracy, most recently the ratio of CSF phosphorylated neurofilamentheavy chain and complement C3, achieving even
higher accuracy (74). CSF based biomarkers may be
useful to aid in the diagnosis of ALS, but may have
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better applications in monitoring drug effects in
clinical trials and as prognostic indicators of disease
(73,75). Further studies, involving samples from
mimic disorders rather than healthy controls, and
serial samples from ALS patients, are required
to validate the candidate diagnostic biomarkers
and fully explore their utility in therapeutic trials.
An important step has been to both recognize
the potential variability in sample quality due to
differences in acquisition and storage (76), and to
establish international consensus on standard operating procedures (77).
Muscle
Skeletal muscle may represent a valuable source of
biomarkers in ALS. This tissue is one of the most
severely affected by the disease, with progressive
denervation and atrophy, and it is easily accessible
to biopsy. The only muscle biomarker that has been
tested prospectively is the axon repellant Nogo-A.
Nogo-A is strongly expressed in ALS muscles, is correlated with ALSFRS and prospectively identifies
patients affected with lower motor neuron disease
that will progress to ALS (78 – 80). However, the
specificity of this increased expression has been
questioned. A combination of biomarkers might
solve the problem of specificity. Muscle transcriptome analyses have identified a number of potential
candidates correlated with disease severity (81).
There are two potential limitations of muscle biomarkers. First, muscle biopsy is invasive and as a
consequence longitudinal studies are very difficult.
Secondly, muscle beds are very differentially involved
among patients. The different sites of onset, as well
as the heterogenous spreading, make it difficult to
standardize the choice of the site of muscle biopsy.
In this respect, the future of muscle biomarkers
might be to identify a set of muscle derived proteins
or peptides that enter the circulation. Such musclederived blood biomarkers could be useful tools to
evaluate disease progression and severity in ALS
patients in a manner similar to creatine kinase for
myopathies.
Skin
The skin is an acknowledged part of the disease
process in ALS, both in experimental models (82)
and humans (83 – 85). Because this organ is easily
accessible and at least some of the biochemical
alterations are related to findings in the CNS
(82,83), the skin is a principal resource of biomarkers for diagnosis, staging, and evaluation of therapy.
The most striking finding is an apparently selective
elevation of the MMP-9 in the skin and spinal cord
of experimental animals and in human skin and the
CSF (82,83). These findings are consistent with
previous observations of increased collagen degradation, in particular collagen types I and IV, in the
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skin of ALS patients (84). The pathogenic steps
responsible for these observations remain to be elucidated; however, free radical damage and inflammation are possible mechanisms. A further discovery
was that small distal epidermal nerve fibers are
affected in ALS (85), indicating the presence of a
small fiber neuropathy. The pattern of changes
reflects the concept of a distal axonopathy and paves
the way for mechanistic studies of cytoskeletal alterations and axonal transport.
Post mortem tissues
While post mortem spinal cord, brain or muscle tissue may not provide the optimal resource for biomarker discovery efforts, they are especially important
to help identify the cell types that express each candidate biomarker, as well as their relationship to the
pathophysiology of the human disease. Increased
efforts to collect ALS and appropriate control post
mortem tissues become more crucial as the multitude of candidate biomarkers identified in the above
mentioned biofluids and tissue biopsies will require
proper characterization and correlation to ALS
pathology. In addition, recent studies have shown
that neural progenitor cells can be cultured from
ALS post mortem tissues and used to generate astrocytes to investigate astrocyte derived cell signalling
that influences motor neuron survival (86). Given
the low numbers of banked ALS tissues at any one
site, standardized collection and storage procedures
for ALS post mortem tissues must be established to
permit use of tissues obtained across multiple sites.
Neurophysiology biomarker sources
EMG and MUNE
Neurophysiological testing has been an important
component of the diagnostic evaluation of patients
with motor neuron disease since the demonstration
that axon loss and consequent reinnervation could
be measured using electromyography (EMG) (87).
While classical EMG and nerve conduction studies
are still incorporated into diagnostic criteria for
ALS (El Escorial), these techniques have not proved
effective in monitoring disease progression or
assessing effects of treatment. Motor unit number
estimation (MUNE) is a tool that was developed
for this purpose. The technique and theoretical
basis for MUNE is quite simple; a maximum
response amplitude, which is generated by activation of all motor units in the muscle, is recorded,
from which an estimate of individual motor unit
number is generated by dividing the maximum
response amplitude by an estimate of single motor
unit amplitude. Many techniques for estimating the
average amplitude of single motor units have been
suggested; most have been limited by sampling bias,
and lack of reproducibility (88).

Recently, a modification of earlier described
techniques was introduced and studied in a natural
history study of patients with ALS (89). Multipoint
incremental MUNE was found to have excellent
test-retest reliability, and to decline monotonically
in ALS faster than other measures traditionally used
in ALS clinical trials. The technique can be well
standardized, is performed briefly with good patient
tolerance, and has a low computational burden.
Using rate of decline as well as variability, hypothetical power analyses suggested that this measure
might reduce both sample size and study duration
in phase II trials. Other new MUNE methods,
including MUNIX (90) and Bayseian MUNE
(91,92) are also being developed. While no physiological method of motor unit number estimation has
been validated against anatomical motor unit counts,
their use as potential endpoints in clinical trials
shows great promise.
Transcranial magnetic stimulation
ALS is diagnosed clinically by the presence of both
UMN and LMN damage. While LMN abnormalities can be confirmed objectively using peripheral
electrodiagnostic methods, UMN findings lack comparable established objective markers. Transcranial
magnetic stimulation (TMS) is a neurophysiological
test that measures UMN functional integrity, and
can detect abnormalities when there are no clinical
UMN signs. TMS works by evoking compound
motor potentials (MEP) using non-invasive magnetic stimulation of the motor cortex through activation of both UMN and LMN pathways. It is used to
study the conductivity and excitability of the corticospinal system. As potential physiological biomarkers, TMS measurements reflect the functional
integrity of the UMN (93).
Single pulse TMS is a well established diagnostic and clinical research tool, although results vary
widely between medical centers. However, if individual laboratories establish their own normative
data, subjects can be tested in a consistent, reliable
fashion. TMS recordings include measurements of
motor threshold, central motor conduction time,
and MEP amplitudes, all of which may be abnormal in ALS (94). TMS also can be delivered in
paired pulses, or as repetitive trains of stimulation
for investigating human brain function, transiently
stimulating or inhibiting different cortical areas
(95,96).
TMS biomarkers, particularly single pulse evoked
TMS amplitude, have been used to objectively discriminate ALS from controls and assess the progression of ALS (97 – 99). TMS can reveal subtle
subclinical UMN dysfunction to help make the diagnosis of ALS as well as clarify the relationship
between ALS and its variants (100), including progressive muscular atrophy where there may be subclinical UMN changes.

Mechanisms, models and biomarkers in ALS
Electrical impedance myography
Electrical impedance myography (EIM) is a technique in which a high-frequency, low-intensity electrical current is applied to a localized area of muscle
and the consequent surface voltages measured (101).
Unlike standard electromyography, in which the
intrinsic electrical activity of muscle is measured,
EIM assesses the integrity and structure of the muscle. An initial, single-center study demonstrated
EIM’s potential power at measuring disease progression in this disease (102). Recently, a second
multicenter study compared EIM directly to the
ALSFRS-R, MUNE, and handheld dynamometry
(103). EIM outperformed the other measures in
terms of its ability to detect deterioration. For example, based on these data, a study that would require
220 subjects using the ALSFRS-R would have the
same power as one with only 95 using EIM. Studies
in ALS rats have similarly showed a strong correlation to the rate of change in EIM and the animal’s
length of survival, as well as to MUNE (104). The
methodology is also being applied in the first North
American study of neural stem cells in ALS (105).
One advantage of EIM over most other modalities is
its ability to assess a variety of muscles and to measure specifically that area of the body where the disease is progressing most rapidly. Measurement of
other muscles not routinely studied but which might
provide valuable data, such as paraspinal muscles
and the tongue, is also possible. Current efforts are
geared toward further refining the technique for easy
use and making it widely available (106).
Neuroimaging biomarker sources
MRI has a major role in the exclusion of cerebral,
and particularly spinal mimics of ALS (107). However, neuroimaging is also at the forefront of advances
in the understanding of in vivo cerebral disease
mechanisms in ALS, including rodent models (108),
with the identification of multiple candidate biomarkers as a result (109).
Radionuclide imaging
Single photon emission computed tomography
(SPECT) is a practical and potentially widely applicable form of radionuclide imaging. It was at the
forefront of the recognition of a clinical, pathological
and, most recently, genetic continuum between ALS
and frontotemporal dementia (FTD) (110). Positron emission tomography (PET) has greater resolution than SPECT but is limited by the availability of
experienced facilities. Pivotal ‘activation’ PET studies, using tracers sensitive to blood flow and metabolism (e.g. radiolabelled water and flurodeoxyglucose,
FDG), provided in vivo evidence for a consistent
extramotor cerebral pathology in ALS (111). Subsequently, ‘ligand’ PET has been used to identify
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specific cerebral neuronal receptor changes in ALS.
Such studies have provided evidence for a loss of
cortical inhibition (112) that might influence progression rate (113), widespread microglial activation
(114), and a striking reduction in serotonin-1A
receptor binding (115), similar to changes seen in
FTD (116). The future value of PET in ALS will
depend upon the development of ligands with relevance to pathogenic hypotheses, e.g. glutamate
receptors, and more specific neuroinflammatory
or protein markers, e.g. TDP-43 (the challenge of
intracellular penetration notwithstanding).
Magnetic resonance imaging (MRI)
The observation of corticospinal tract hyperintensity
lacks sensitivity and specificity for the diagnosis of
ALS. Routine clinical structural imaging of the brain
has limited value as a source of biomarkers in ALS,
and only through advanced analysis methods (117).
The acquisition of high-resolution 3D T1-weighted
images and the development of novel pulse sequences
such as diffusion tensor imaging and functional MRI
have greatest potential in this regard, and would ultimately be feasible to perform within the clinical environment (118).
Macroscopic atrophy of the motor cortex is not
a consistent observation in ALS, although prominent
in those with PLS. Sophisticated analysis of 3D
T1-weighted structural images acquired in 3D,
known as voxel-based morphometry (VBM), can
reveal subtle changes in regional cerebral tissue. Several VBM studies have been performed in ALS, and
meta-analysis showed the right precentral gyrus as
consistently altered (119). Surface-based morphometry allows assessment of cortical thickness, and a
study in ALS confirmed not only primary motor, but
also extramotor, temporal cortical thinning in faster
progressors (120).
Post mortem histopathological study first demonstrated widespread cerebral white matter tract
damage in ALS (121) and this can now be detected
non-invasively using diffusion tensor imaging (DTI).
This advanced MRI technique is sensitive to the
movement of water, normally directionally confined
within neuronal tracts. The two main quantitative
measures of loss of neuronal tract integrity are
reduced fractional anisotropy (FA) and increased
mean diffusivity. Related parameters such as
increased radial diffusivity may specifically reflect
secondary demyelination of tracts in ALS. DTI studies have shown consistently reduced FA in the corticospinal tract, particularly within the posterior limb
of the internal capsule (PLIC) (122) and corpus callosum (123) of ALS patients. Targeted FA measurement at the PLIC may provide prognostic information
(124). DTI measures may, however, be insufficiently
sensitive to longitudinal change over less than six
months (125), nor have sufficient discriminatory
power as an isolated measurement (126).
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MRI is unsurpassed in its spatial resolution of
cerebral functional activity achieved non-invasively.
Blood oxygenation level-dependent (BOLD) functional MRI (fMRI) studies of motor tasks in ALS
patients confirmed the widened region of activation
observed in PET studies. More recently, however,
it is the study of the ‘resting state’ that provides
novel insight into ALS as a ‘system failure’. Resting-state fMRI (R-fMRI) has demonstrated
increased functional connectivity within the damaged ALS cortical network, with possible implications in relation to cortical inhibitory influences
(127). The combination of structural and functional MRI measures in this study also provided
much better separation of patients from healthy
age-matched controls.
Magnetic resonance spectroscopy (MRS) is an
application of MRI that permits quantification of
cerebral tissue metabolites. It has consistently demonstrated reduced N-acetylaspartate ratios (a nonspecific marker of neuronal loss) in the motor
cortex of ALS patients, and high-field studies also
suggest a specific loss of GABA-ergic influence
(128). Recent studies applied to the cervical spinal
cord of pre-symptomatic carriers of pathological
SOD1 gene mutations demonstrated metabolite
changes more consistent with affected ALS patients
rather than healthy non-gene carriers (129), suggesting that MRS may be particularly sensitive to
pre-clinical changes. This offers the hope of capturing the very earliest events in individuals carrying
genetic abnormalities associated with the development of ALS, with the possibility of wider translation to sporadic cases.
The challenge for neuroimaging biomarker candidates is to move beyond results based on group
averages, to individual measurements. It seems likely
that this will require multiple parameters. Further
longitudinal studies are needed to assess the sensitivity of multimodal MRI to disease activity compared to clinical assessments such as ALSFRS.
Concluding remarks
Major advances in the understanding of the pathobiology of ALS have occurred over the last two
decades with developments in molecular biology,
immunocytochemistry, neurophysiology and neuroimaging, and the recognition of overlap with
some forms of FTD. It seems increasingly likely
that there are multiple, possibly more discrete,
pathways converging on motor neuron death. While
recent discoveries in relation to RNA biology hint
at a massively under-estimated level of pathological complexity in ALS, the common theme of misfolded protein inclusions across the range of
neurodegenerative disorders brings the hope of a
common strategy for the treatment of pre-aggregation events (130) and for common biomarker
development. Biomarker candidates are emerging

with the potential to refine the diagnosis, stratify
patients prognostically, and facilitate therapeutic
development. A key aim for further biomarker
development, beyond validation across multiple
centers, is the routine incorporation of biomarker
measurement into future clinical trials.
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